Dose reduction potential of nanoparticle ARV formulations confirmed in humans
Date:
4/24/17
​First in-human trial results of nanoformulations of efavirenz and lopinavir confirmed the potential for a 50% dose reduction to the current standard oral dose of both antiretrovirals.